Researchers grow functional pancreatic beta cells from stem cells

By Monish Makena, The Science Advisory Board contributing writer

March 9, 2022 -- A research group has demonstrated that stem cells can form cells that closely mimic normal pancreatic islets, in terms of both structure and function. The findings, which were published in Nature Biotechnology on March 3, show how stem cell islets can be used as tools for diabetes research and cell therapies.

A primary goal of stem cell research is the generation of functional pancreatic beta cells from human pluripotent stem cells, as insulin is a vital hormone produced by pancreatic beta cells. Type 1 diabetes is caused by the destruction of these pancreatic cells. However, insulin secretion can be restored in diabetic patients by transplanting beta cells isolated from the pancreas of a brain-dead organ donor.

pancreatic beta cells from stem cells
The picture shows a pancreatic islet produced from stem cells. Insulin-producing cells are shown in red and glucagon-producing cells in green. Image courtesy of Otonkoski Lab/University of Helsinki.

Attempts have been made to produce functional beta cells from stem cells, which could make this treatment increasingly common. However, the beta cells produced from stem cells have so far been immature, with poorly regulated insulin secretion. For researchers, the end goal is to provide a consistent and renewable source of cells to treat diabetes in patients.

In this research study, led by Diego Balboa, PhD, of the University of Helsinki, the authors generated functionally mature stem cell-derived islets (SC-islets) using an optimized protocol and comprehensively benchmarked them against primary adult islets. The electrophysiology and exocytosis of SC-islets were comparable to adult islets, and they were able to achieve glucose-responsive insulin secretion despite differences in glycolytic and mitochondrial glucose metabolism. Murine engraftment revealed a resemblance to that of primary islets.

The study demonstrated that the combination of integrated analyses with refined differentiation protocols can guide the generation of further improved SC-islets for the modeling of beta cell dysfunction, drug screening purposes, and cell replacement approaches, expanding the understanding of the disease mechanisms and therapeutic possibilities to combat diabetes, according to the study.

"This study will help further improve the production of stem cell islets, which will make it easier to utilize them in disease modeling and cell therapies," Timo Otonkoski, PhD, of the University of Helsinki, said.

The authors believe that this research could prove valuable to the scientific community.

"I believe the international scholarly community values our efforts to validate stem cell islets as tools for diabetes research and cell therapies," Anders Tengholm, PhD, of Uppsala University in Sweden, said.

Human Cell Design launches advanced human beta cell model
Human Cell Design has launched Endoc-BH5, the fifth version of its model of ready-to-use functional human pancreatic beta cells.
Cellular programming spurs next-generation cell therapies
Cellular reprogramming of ex vivo cells may offer improvements on first-generation adoptive cell therapies, which have experienced limited clinical success...
NIH awards $2.59M for diabetes gene therapy
Gene therapy technology developer Genprex said that the U.S. National Institutes of Health (NIH) has awarded a $2.59 million grant to the University...
Microscopy with fluorescent tags gives high-def view of diabetes-related proteins
Leveraging the power of new imaging techniques, scientists are using unique fluorescent tags in combination with superresolution microscopy to gain novel...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter